Watch our oral testimony at the FDA Advisory Committee meeting on March 22, 2023. We are grateful to the FDA Advisory Committee for reviewing the evidence, listening to the ALS community and voting to recommend accelerated approval of tofersen for …
Oral Testimony to the FDA Advisory Committee on the Approval of tofersen
Delivered by Lauren Webb, LCSW, Chief Advocacy and Outreach Officer of the Les Turner ALS Foundation. See also remarks by Senda Ajroud-Driss, MD, Director of the Lois Insolia ALS Clinic at the Les Turner ALS Center at Northwestern Medicine. Open …
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
Today was a tough call for the ALS community, but not entirely disheartening. BrainStorm released the topline results this morning (November 17) from its Phase 3 trial for NurOwn® showing it did not meet statistical significance in its primary efficacy …
Amylyx Publishes CENTAUR Survival Data Demonstrating Statistically Significant Survival Benefit of AMX0035 for People with ALS
We are excited to share some promising data regarding the CENTAUR trial evaluating AMX0035 in people with ALS on overall survival analysis, published today (October 16, 2020) in the neuromuscular disease journal Muscle & Nerve. The survival analysis followed each …
Data from Amylyx’s CENTAUR trial shows promise in slowing ALS progression
We are very pleased to share promising data published this week in the New England Journal of Medicine from the recent CENTAUR trial, conducted by Amylyx Pharmaceuticals, showing that AMX0035, the combination drug of sodium phenylbutyrate–taurursodiol, can slow functional decline …
August 2020 Foundation eNews
New and Improved Clinical Trials Webpage While it may feel like much in life is on pause at the moment, there is exciting news in the ALS clinical trials and studies space, including information on the upcoming HEALEY ALS Platform …
Presentamos el Primer Ensayo Plataforma de ELA
El Centro Sean M. Healey & AMG del Hospital General de Massachusetts está lanzando el primer ensayo plataforma de ELA, diseñado para avanzar en el desarrollo de tratamientos para esta enfermedad. Nuestra Clínica de ELA Lois Insolia en el Centro …
